Literature DB >> 32658352

Refractory acquired thrombotic thrombocytopenic purpura treated with caplacizumab in a pediatric patient with systemic lupus erythematosus.

Margaret B Nagel1, Alex Ryder2, Monica Lobbins3, Nidhi Bhatt1.   

Abstract

Entities:  

Year:  2020        PMID： 32658352     DOI： 10.1002/pbc.28534

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


× No keyword cloud information.
  3 in total

1.  Thrombotic thrombocytopenic purpura temporally associated with BNT162b2 vaccination in an adolescent successfully treated with caplacizumab.

Authors:  Amrit Kirpalani; Justin Garabon; Kiersten Amos; Serina Patel; Ajay P Sharma; Saptharishi Lalgudi Ganesan; Michelle Barton; Chantel Cacciotti; Sarah Leppington; Linda Bakovic; Shih-Han Susan Huang; Michael J Knauer; Soumitra Tole
Journal:  Br J Haematol       Date:  2021-08-17       Impact factor: 8.615

2.  The Efficacy and Safety of Plasma Exchange in the Treatment of Thrombotic Thrombocytopenic Purpura.

Authors:  Zhilan Pan; Zhimin Zhang; Yan Yang; Weihua Hao
Journal:  J Healthc Eng       Date:  2022-03-31       Impact factor: 2.682

3.  Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura.

Authors:  Martin Bergstrand; Emma Hansson; Bernard Delaey; Filip Callewaert; Rui De Passos Sousa; Maria Laura Sargentini-Maier
Journal:  J Clin Pharmacol       Date:  2021-11-29       Impact factor: 2.860
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.